Acrux Limited (AU:ACR) has released an update.
Acrux Limited is set to host an Investor Webinar on December 17 to update shareholders and investors on the commercialisation of its Nitroglycerin 0.4% ointment. Acrux, a specialty pharma company, has a strong track record in developing topical pharmaceutical products and is seeking to expand its market presence through partnerships and new product developments.
For further insights into AU:ACR stock, check out TipRanks’ Stock Analysis page.